Subcutaneous · GLP-1 / GIP / glucagon triple
Efocipegtrutide
3 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
3
Active
1
Recruiting
0
Completed
2
Sites
62
Countries
2
Endpoints
7
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
2
1
1
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT04505436Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects | Efocipegtrutide MASH / NAFLD / liver fibrosis | BMI ≥18 | Ph 2 | Active, not recruiting | 60 | Jun 2026 | — | |
| NCT03374241A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide) | Efocipegtrutide Healthy volunteers, Obesity / overweight | — | Ph 1 | Completed | 1 | Sep 2018 | — | results |
| NCT03744182A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD | Efocipegtrutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥30 | Ph 1 | Completed | 1 | Mar 2020 | — | results |